Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

August 31, 2025

Conditions
Usher Syndromes
Interventions
DRUG

NPI-001

oral tablet

OTHER

Placebo

Placebo tablets

Trial Locations (4)

Unknown

Queensland Eye Institute, Brisbane

CERA, Melbourne

Lions Eye Institute, Perth

Sydney Eye Hospital / Save Sight Institute, Sydney

Sponsors
All Listed Sponsors
collaborator

Foundation Fighting Blindness

OTHER

lead

Nacuity Pharmaceuticals, Inc.

INDUSTRY

NCT04355689 - Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome | Biotech Hunter | Biotech Hunter